Skip to main content
SpringerLink
Log in

Prescribing Information for Antihypertensive Medications Lacks Dose-Specific Blood Pressure Response

  • Letter to the Editor
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens. 2020;38(6):982–1004.

    Article  CAS  Google Scholar 

  2. Geldsetzer P, Manne-Goehler J, Marcus ME, et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1·1 million adults. Lancet. 2019;394(10199):652–62.

    Article  Google Scholar 

  3. NCD Risk Factor Collaboration (NCD-RisC). Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet. 2019;394(10199):639–51.

    Article  Google Scholar 

  4. European Commission. A Guideline on Summary of Product Characteristics October 2005. http://www.kardio.hr/wp-content/uploads/2012/12/spcguidrev1-oct2005_en.pdf. Accessed 28 May 2021.

  5. Federal Register. Tuesday, January 24, 2006. Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products. https://www.govinfo.gov/content/pkg/FR-2006-01-24/pdf/06-545.pdf. Accessed 28 May 2021.

  6. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products—Content and Format. https://www.fda.gov/media/72140/download. Accessed 28 May 2021.

  7. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Labeling for Human Prescription Drug and Biological Products–Implementing the PLR Content and Format Requirements. https://www.fda.gov/media/71836/download. Accessed 28 May 2021.

  8. Sullivan HW, O’Donoghue AC, Aikin KJ. Primary care physicians’ use of FDA-approved prescription drug labels. J Am Board Fam Med. 2014;27(5):694–8.

    Article  Google Scholar 

  9. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in J Am Coll Cardiol. 201815;71(19):2275–2279]. J Am Coll Cardiol. 2018;71(19):e127–e248.

Download references

Funding

N/A.

Author information

Authors and Affiliations

  1. School of Pharmacy, University of Maryland Baltimore, 20 N. Pine Street, Baltimore, MD, 21201, USA

    Ruchi Vyas PharmD Candidate & Catherine E. Cooke PharmD, MS, BCPS, PAHM

Authors
  1. Ruchi Vyas PharmD Candidate
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catherine E. Cooke PharmD, MS, BCPS, PAHM
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Dr. C.E.C. and R.V. designed the research. R.V. wrote the manuscript. Dr. C.E.C. and R.V. edited the manuscript and contributed analytical tools. R.V. analyzed the data.

Corresponding author

Correspondence to Ruchi Vyas PharmD Candidate.

Ethics declarations

Conflict of interest

No conflict of interest to be declared by either author.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vyas, R., Cooke, C.E. Prescribing Information for Antihypertensive Medications Lacks Dose-Specific Blood Pressure Response. Ther Innov Regul Sci 55, 1101–1102 (2021). https://doi.org/10.1007/s43441-021-00314-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s43441-021-00314-8

Search

Navigation